Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18636437 | 0.89 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL18636474 | 0.86 | TMPRSS2 (0.31) | TMPRSS2 | |
| SCHEMBL20878404 | 0.85 | TMPRSS2 (0.32) | TMPRSS2 | |
| SCHEMBL21283650 | 0.84 | CYP3A4 (0.33) | TMPRSS2RIPK1 | |
| SCHEMBL18636611 | 0.83 | TMPRSS2 (0.34) | TMPRSS2 | |
| SCHEMBL20078702 | 0.83 | TMPRSS2 (0.33) | TMPRSS2RIPK1 | |
| SCHEMBL26295060 | 0.82 | TMPRSS2 (0.43) | TMPRSS2 | |
| SCHEMBL26327372 | 0.82 | TMPRSS2 (0.31) | TMPRSS2RIPK1 | |
| SCHEMBL20078677 | 0.81 | TMPRSS2 (0.40) | TMPRSS2RIPK1 | |
| SCHEMBL10154198 | 0.81 | TMPRSS2 (0.36) | TMPRSS2RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4219513-A1 | CRYSTALLINE FORM OF (S)-2-ETHYLBUTYL 2-(((S)-(((2R,3S,4R,5R)-5-(4-AMINOPYRROLO[2,1-F] [1,2,4]TRIAZIN-7-YL)-5-CYANO-3,4-DIHYDROXYTETRAHYDROFURAN2-YL)METHOXY)(PHENOXY) PHOSPHORYL)AMINO)PROPANOATE | Gilead Sciences, Inc. (US) | 2023-08-02 | — | — | EP | disclosed |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2022-03-08 | — | — | US | disclosed |
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | GILEAD SCIENCES, INC. | 2021-02-25 | — | — | US | disclosed |
| US-9949994-B2 | Methods for treating Filoviridae virus infections | GILEAD SCIENCES, INC. (US) | 2018-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210052613-A1 | METHODS FOR TREATING FILOVIRIDAE VIRUS INFECTIONS | PNP, PRPF4, RPIA | TMPRSS2 1951/4885RIPK1 2292/4885 |
| US-11266666-B2 | Methods for treating Filoviridae virus infections | PNP, PRPF4, RPIA | TMPRSS2 1951/4885RIPK1 2292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.